image credit: Adobe Stock

Alzheimer’s drug Leqembi to launch at discount to Aduhelm

January 9, 2023


The US regulator has granted accelerated approval to anti-amyloid therapy Leqembi (lecanemab) with a fairly broad label to treat patients in the mild cognitive impairment or mild dementia stage of disease who have confirmed presence of amyloid pathology.

Eisai and Biogen have said they have already submitted a supplemental filing to the FDA to upgrade that to a full, non-conditional approval.

Read More on Pharmaphorum